Thomas MBA - NanoString Technologies Chief Officer
| NSTGDelisted Stock | USD 4.11 0.22 5.08% |
Insider
Thomas MBA is Chief Officer of NanoString Technologies
| Age | 55 |
| Phone | 206 378 6266 |
| Web | https://www.nanostring.com |
NanoString Technologies Management Efficiency
The company has return on total asset (ROA) of (0.3087) % which means that it has lost $0.3087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.2856) %, meaning that it created substantial loss on money invested by shareholders. NanoString Technologies' management efficiency ratios could be used to measure how well NanoString Technologies manages its routine affairs as well as how well it operates its assets and liabilities.NanoString Technologies currently holds 250.5 M in liabilities with Debt to Equity (D/E) ratio of 2.22, implying the company greatly relies on financing operations through barrowing. NanoString Technologies has a current ratio of 6.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about NanoString Technologies' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael SchnallLevin | 10X Genomics | N/A | |
| Courtney Solberg | Syros Pharmaceuticals | N/A | |
| Jim Wilbur | 10X Genomics | N/A | |
| Eric Esq | 10X Genomics | 57 | |
| Serge Saxonov | 10X Genomics | 47 | |
| Madan Jagasia | Iovance Biotherapeutics | N/A | |
| David MBA | Seres Therapeutics | 63 | |
| Tracy Morris | Veracyte | N/A | |
| Jason Haas | Syros Pharmaceuticals | 56 | |
| James MD | Syros Pharmaceuticals | 52 | |
| Esq JD | Iovance Biotherapeutics | 48 | |
| Howard MBA | Iovance Biotherapeutics | 64 | |
| Marc Stapley | Veracyte | 54 | |
| Jonathan Wygant | Veracyte | 53 | |
| Annie McGuire | Veracyte | 44 | |
| JeanMarc MBA | Iovance Biotherapeutics | 52 | |
| David MD | Syros Pharmaceuticals | 61 | |
| Igor Bilinsky | Iovance Biotherapeutics | 51 | |
| Benjamin Hindson | 10X Genomics | 49 | |
| Ruth Backer | 10X Genomics | 47 | |
| Friedrich MD | Iovance Biotherapeutics | 57 | |
Management Performance
| Return On Equity | -10.29 | |||
| Return On Asset | -0.31 |
NanoString Technologies Leadership Team
Elected by the shareholders, the NanoString Technologies' board of directors comprises two types of representatives: NanoString Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NanoString. The board's role is to monitor NanoString Technologies' management team and ensure that shareholders' interests are well served. NanoString Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NanoString Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Todd Garland, Chief Officer | ||
| Joseph Beechem, Chief Development | ||
| Mark Winham, Senior Operations | ||
| Chad Brown, Senior Vice President - Sales and Marketing | ||
| Thomas MBA, Chief Officer | ||
| Elizabeth Schneider, Senior Manager | ||
| Kathryn SuraceSmith, Senior Secretary | ||
| Praveer Sharma, Field Scientist | ||
| Bradley Gray, CEO and President and Director | ||
| David Ghesquiere, Senior Vice President - Corporate & Business Development | ||
| Anne Valk, Executive | ||
| Mary Allen, Vice President - Operations | ||
| Douglas Farrell, Vice Communications | ||
| Philippa Webster, Senior Scientist |
NanoString Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NanoString Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.29 | |||
| Return On Asset | -0.31 | |||
| Profit Margin | (1.02) % | |||
| Operating Margin | (0.76) % | |||
| Current Valuation | 153.97 M | |||
| Shares Outstanding | 48.12 M | |||
| Shares Owned By Insiders | 3.16 % | |||
| Shares Owned By Institutions | 96.84 % | |||
| Number Of Shares Shorted | 6.04 M | |||
| Price To Earning | (4.62) X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in NanoString Stock
If you are still planning to invest in NanoString Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NanoString Technologies' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |